Trials / Withdrawn
WithdrawnNCT04210726
Effect of Salt Solution Immersion Bath on Cancer in Vivo.
Effect of Human Body Immersion in Hypertonic Saline Solution on Cancer Nodules' Size, Number and Its Metastasis Properties in Vivo.
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Rafik Batroussy · Academic / Other
- Sex
- All
- Age
- 5 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This Study evaluates the effectiveness of Hypertonic Saline Bath in reducing the Cancer nodules' size, number and SUVmax.
Detailed description
Many previous studies have shown that the Cancer cells are over-hydrated, and that Hyponatraemia exists in many cases of Cancer. The Cancer cell's viability depends on Angiogenesis and formation of blood vessels that carry water and nutrient to the rapidly-dividing Cancer cells. This study tests the hypothesis that disrupting the water content of blood could lead to increasing its Tonicity and hence withdrawing water from the Cancer cells by Osmosis, which can result in disrupting the growth of the Cancer cell itself. This disruption of Blood Water content can be achieved using Osmotic Pressure differential via immersing the whole body in Hypertonic Saline Solution for a certain amount of time, thus making the Blood more Hypertonic relative to the cells of the body and of the cancer, leading to water withdrawal from the cells of the body and of the cancer. While body's cells can sustain temporary dehydration, Cancer cells could be negatively affected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 25% Hypertonic Saline Bath | 25% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 25%). |
| OTHER | 0.9% Isotonic Saline Bath | 0.9% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 0.9%). |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2020-12-01
- Completion
- 2021-03-01
- First posted
- 2019-12-26
- Last updated
- 2023-07-27
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04210726. Inclusion in this directory is not an endorsement.